Rhumbline Advisers Acquires 7,725 Shares of Sientra Inc (SIEN)
Rhumbline Advisers grew its holdings in Sientra Inc (NASDAQ:SIEN) by 55.6% during the 2nd quarter, Holdings Channel reports. The firm owned 21,621 shares of the medical instruments supplier’s stock after purchasing an additional 7,725 shares during the period. Rhumbline Advisers’ holdings in Sientra were worth $422,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Commonwealth Equity Services LLC bought a new position in shares of Sientra in the 2nd quarter valued at about $210,000. Barclays PLC boosted its stake in shares of Sientra by 133.7% in the 1st quarter. Barclays PLC now owns 31,521 shares of the medical instruments supplier’s stock valued at $304,000 after purchasing an additional 18,033 shares during the last quarter. First Mercantile Trust Co. bought a new position in shares of Sientra in the 2nd quarter valued at about $427,000. Emerald Advisers Inc. PA bought a new position in shares of Sientra in the 2nd quarter valued at about $527,000. Finally, Columbia Partners L L C Investment Management bought a new position in shares of Sientra in the 2nd quarter valued at about $975,000. 89.21% of the stock is currently owned by institutional investors.
In related news, CEO Jeffrey M. Nugent sold 1,852 shares of Sientra stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $24.90, for a total transaction of $46,114.80. Following the transaction, the chief executive officer now owns 297,999 shares of the company’s stock, valued at approximately $7,420,175.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 31.00% of the stock is owned by company insiders.
Sientra stock opened at $24.33 on Friday. Sientra Inc has a fifty-two week low of $8.79 and a fifty-two week high of $26.79. The company has a market cap of $677.72 million, a P/E ratio of -8.63 and a beta of -0.79. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.63 and a current ratio of 3.06.
Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Tuesday, August 7th. The medical instruments supplier reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.04). Sientra had a negative return on equity of 151.47% and a negative net margin of 131.16%. The firm had revenue of $17.55 million for the quarter, compared to the consensus estimate of $15.30 million. analysts expect that Sientra Inc will post -2.93 EPS for the current fiscal year.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Recommended Story: What is Considered a Good Return on Equity (ROE)?
Want to see what other hedge funds are holding SIEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sientra Inc (NASDAQ:SIEN).
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.